Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
University of Florida
University of Florida
Northside Hospital, Inc.
Rush University Medical Center
Janssen Research & Development, LLC
Washington University School of Medicine
Yale University
Sensei Biotherapeutics, Inc.
Kiadis Pharma
Immune System Key Ltd
City of Hope Medical Center
University of Pittsburgh
Jazz Pharmaceuticals
Masonic Cancer Center, University of Minnesota
Cornerstone Pharmaceuticals
Mesoblast, Ltd.
University of California, San Francisco
M.D. Anderson Cancer Center
European Society for Blood and Marrow Transplantation